Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
In February 2024, Larimar raised net proceeds of approximately $161.8 million through a public offering of common stock.
- In February 2024, Larimar raised net proceeds of approximately $161.8 million through a public offering of common stock.
- In March 2024, Larimar began to build its commercial team with the appointment of Frank Nazzario, RPh, as Vice President of Commercial.
- Research and development expenses for the first quarter of 2024 were $12.9 million, compared to $4.6 million for the first quarter of 2023.
- General and administrative expenses were $3.8 million in the first quarter of 2024, compared to $3.1 million in the first quarter of 2023.